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Objectives: Apoptosis caused by acute ischemia and subsequent ventricular remod-
eling is implicated as a mediator of heart failure. This study was designed to assess
the efficacy of in vivo viral gene transfer of the antiapoptotic factor apoptosis
repressor with caspase recruitment domain to block apoptosis and preserve ventric-
ular geometry and function.
Methods: In a rabbit model of regional ischemia followed by reperfusion, an
experimental group treated with adenovirus-apoptosis repressor with caspase re-
cruitment domain was compared with empty vector adenovirus-null controls. Car-
diac function was assessed by echocardiography and sonomicrometry of the border
zone compared with the normal left ventricle. Animals were killed at 6 weeks with
measurements of ventricular geometry and apoptosis.
Results: Animals with the apoptosis repressor with caspase recruitment domain
(ARC group) maintained higher ejection fractions at 4 and 6 weeks, and sonomi-
crometry demonstrated greater protection of border zone fractional shortening at 6
weeks compared with the control group. The ARC group maintained superior
preservation of left ventricular geometry with less ventricular dilation and wall
thinning. Finally, there was reduced apoptosis in the rabbits treated with apoptosis
repressor with caspase recruitment domain compared with the controls.
Conclusions: Gene transfer of apoptosis repressor with caspase recruitment domain
preserves left ventricular function after ischemia. The benefit at 6 weeks is postu-
lated to result from an apoptosis repressor with caspase recruitment domain–
mediated reduction in apoptosis and ventricular remodeling. Adenovirus-apoptosis
repressor with caspase recruitment domain administration offers a potential strategy
after myocardial ischemia to protect the heart from late postischemic cardiomyop-
athy.
Ventricular injury after myocardial infarction can lead to progres-sive chamber enlargement and ventricular wall thinning. Wallthinning occurs in the infarcted region and the border zone (BZ)between the ischemic segment and the noninfarcted viable myo-cardium.1 The interaction of the area of infarction with remainingmyocardium results in supraphysiologic stretch across the BZ,
which augments the tension load.2 Because of the heightened wall tension, the
ventricle remodels and undergoes dilation. With progressive ventricular dilation,
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there is failure to maintain a compensatory proportional
increase in wall thickness. Consequently, the wall thickness/
chamber radius ratio is not preserved, resulting in increased
wall tension and decompensated eccentric ventricular hy-
pertrophy and a decline in ventricular function.3
Although postischemic heart failure may have multiple
causes, recent attention has been directed toward under-
standing the contribution of apoptosis or programmed cell
death. Apoptosis is characterized by preservation of mito-
chondrial and sarcolemmal membranes, nuclear chromatin
condensation, and phagocytosis by macrophages or neigh-
boring cells without triggering an inflammatory response. It
has been demonstrated in animal models and human pa-
tients after ischemia/reperfusion injury, myocardial infarc-
tion, congestive heart failure, and ischemic cardiomyopa-
thy.4-6 It has recently been proposed that progressive
ventricular dysfunction after infarction is the result of on-
going loss of cardiomyocytes from apoptosis.7
The activation of apoptosis is known to occur through 2
separate mechanisms (Figure 1)8,9 involving caspases, a
family of cysteine proteases that are synthesized as inactive
precursors and proteolytically cleaved into their active
form.10 The first mechanism has been termed the death
receptor or extrinsic pathway. In this pathway, ligand-
binding to a death receptor such as tumor necrosis factor
receptor–1 recruits intracellular adaptor proteins such as
tumor necrosis factor receptor–1–associated death domain
and then Fas-associated death domain to bind procaspase-8,
which is then cleaved into caspase-8.
The second major mechanism is the mitochondrial or
intrinsic pathway. Mitochondria play a critical role in apo-
ptosis, with the cytochrome c step in the electron transport
chain the most vulnerable to disruption.11,12 When exposed
to hypoxia and ischemia/reperfusion injury, mitochondria
release cytochrome c into the cytosol to form a complex
with the apoptosis activating factor (Apaf-1) and pro-
caspase-9.13 This complex is facilitated by a caspase-asso-
ciated recruitment domain located on Apaf-1. Subsequently,
the cytochrome c/Apaf-1/procaspase-9 complex activates
caspase-9. Finally, both the extrinsic pathway involving
caspase-8 and the intrinsic pathway involving caspase-9
share a final common pathway and activate the downstream
effector caspase-3, resulting in apoptotic cell death.8
An anti-apoptotic factor, the apoptosis repressor with
caspase recruitment domain (ARC), demonstrates in vitro
evidence of blocking both the intrinsic and extrinsic path-
ways (Figure 1). ARC is expressed almost exclusively in
myogenic tissue and selectively interacts with the initiator
caspases 2 and 8 attenuating death receptor-mediated in-
duced apoptosis.14 It also blocks apoptosis associated with
caspase-independent events such as hypoxia-induced cyto-
chrome c release from the mitochondria.15 Finally, ARC can
also prevent cellular changes associated with necrotic cell
death by preventing mitochondrial dysfunction.16
Figure 1. Pathways of apoptosis and site of action of ARC. Major pathways involved in the apoptotic cascade
include extrinsic (death receptor pathway) and intrinsic (mitochondrial) pathway. ARC has been demonstrated to
block the caspase 8 step of extrinsic pathway and release of cytochrome c in the intrinsic pathway.
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In this study, we analyzed the effect of administering
adenovirus-ARC (Adeno-ARC) after myocardial ischemia
to determine its protective role in preventing the develop-
ment of postischemic heart failure. After the initial isch-
emia/reperfusion injury, immediate cell death occurs in the
infarcted zone by necrosis and apoptosis. As the ventricle
remodels and the infarction proceeds to stiffen, we postulate
that apoptosis persists at a low level in the BZ. Continued
cell death and the loss of myocytes in this region may lead
to ventricular dilatation and dysfunction. As a result, block-
ing apoptosis may reduce the drive toward continued ven-
tricular dilation and preserve myocardial function. This
would allow targeted gene therapy to be an adjunct to
standard therapies after myocardial infarction in an effort to
prevent subsequent postischemic heart failure.
Methods
Adenoviral Vector Construction/Viral Delivery
Replication-deficient adenoviral vector containing the transgene
encoding human ARC with a constitutively active cytomegalovi-
rus promoter was prepared as previously described.16 Empty vec-
tor Adeno-null virus17 (no transgene) with a cytomegalovirus
promoter was constructed for controls. To demonstrate gene trans-
fection using this method of viral delivery, an adenovirus construct
encoding the reporter gene -galactosidase (-Gal) was adminis-
tered, and calculation of gene transfection was determined by
scanning three sections through the BZ into Adobe Photoshop
(Adobe Systems Incorporated, San Jose, Calif) (Figure 2).
Animal Surgery
All animals received humane care in compliance with institutional
guidelines and the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal Re-
sources, National Research Council, and published by the National
Academy Press, revised 1996. Twenty-one New Zealand White
rabbits (3-4 kg) were used. All rabbits were anesthetized with
intramuscular doses of ketamine (40 mg/kg), xylazine (2.5 mg/kg),
glycopyrrolate (0.02 mg/kg), and buprenorphine (0.05 mg/kg),
orally intubated, and mechanically ventilated (Hallowell EMC
model 2000, Pittsfield, Mass). A left thoracotomy was performed
through the third intercostal space and a 6-0 polypropylene suture
was placed around the circumflex artery halfway between the
atrioventricular groove and the left ventricular (LV) apex. Both
ends of the suture were placed through a red rubber catheter
creating a tourniquet that was tightened to achieve complete ces-
sation of flow as demonstrated by electrocardiographic changes
and visual blanching. After 30 minutes, the tourniquet was re-
leased for reperfusion. The suture marking the site of occlusion
remained facilitating identification of the BZ when the animal was
put to death.
Next, the pulmonary artery (PA) and ascending aorta were each
encircled with a 0-0 silk suture and red rubber tourniquet. The PA
tourniquet was tightened for complete PA occlusion, and the left
atrium and ventricle allowed to empty for 5 seconds before the
aortic tourniquet was tightened. A solution of 1000 L containing
5.0  1010 particle-forming units of recombinant human Ad-
CMV-ARC (n  8), suspended in 10% glycerol, was injected into
the LV cavity. The control group received 1000 L of 5.0  1010
particle-forming units of Adeno-null (n  7) empty vector. After
30 seconds of complete outflow occlusion, the tourniquets were
removed, the chest was closed, and the animal recovered without
operative intervention for 6 weeks. During this interval, the animal
was studied with transthoracic echocardiography at 2-week inter-
vals, and there was 1 operative death (1/16 6.3% mortality rate).
An additional group of 5 native rabbits were used to demonstrate
normal measurements of LV ejection fraction and ventricular
geometry.
After 6 weeks the animal was returned for nonsurvival surgery.
A repeat left thoracotomy exposed the LV free wall. Four 1-mm
piezoelectric sonomicrocrystals (Sonometrics Corp, London, On-
tario, Canada) were implanted into the myocardium to measure
fractional shortening. After sonomicrometry, the heart was ar-
rested in diastole with 1 mL KCl (1 mEq/mL), and the right atrium
was incised to allow drainage of blood. The heart was procured
and the LV cavity filled with O.C.T. embedding compound (Tis-
sue-Tek O.C.T. or optimal cutting compound; Sakura Finetek,
Torrance, Calif) retrogradely through the transected aortic root
with a gravity driven pressure reservoir to ensure constant intra-
cavitary pressure. The catheter was removed, the aortic root was
ligated, and the heart was placed in a container of O.C.T. embed-
ding compound, bathed in isopentane, frozen in liquid nitrogen,
and stored in a freezer at 80°C.
Functional Analysis
Functional analysis was studied by transthoracic echocardiography
and sonomicrometry, a well-established technique measuring LV
segmental length changes during each cardiac cycle to measure
regional contractility. Data were analyzed with Sonoview software
(Sonometrics Corp, London, Ontario, Canada) and reported as a
percentage of normal contractility SEM. Two sonomicrocrystals
were placed within the ischemic segment (“in” position) 10 mm
apart from each other, and 2 sonomicrocrystals within the viable
myocardium outside the infarct zone (“out” position) 10 mm apart.
Figure 2. Immunoblotting. Rabbit anti-human polyclonal ARC was
used to probe samples at 6 weeks after infarction. There is
significant increase in ARC expression in the Adeno-ARC–treated
group compared with Adeno-null controls. Samples were also
stained for actin to demonstrate equivalent loading conditions.
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Fractional shortening is defined as the difference between the
end-diastolic length and the end-systolic length divided by the
end-diastolic length (the distance between the crystals). Contrac-
tility across the BZ was measured by assessing segmental length
changes between a crystal in the “in” position with the ipsilateral
(in relation to the tourniquet site of occlusion) “out” crystal 10 mm
apart. Normal contractility was measured between the 2 “out”
crystals.
Ventricular Geometry: Chamber Size and Wall
Thickness
Four adjacent sections, midway between the base and the apex,
spanning the BZ and perpendicular to the LV longitudinal axis,
were obtained from each heart to measure chamber luminal diam-
eter and free wall thickness. Four investigators, blinded to the
treatment groups, analyzed each section. For the measurement of
chamber size, LV diameter was recorded in both the vertical and
horizontal axes, and mean values of each slice were averaged. Five
equally spaced measurements of the LV free wall from each slice
were used to determine wall thickness with an ocular dissecting
microscope accurate to 0.03 mm. Five native rabbits were used to
demonstrate chamber diameter and wall thickness in uninfarcted
and untreated animals.
TUNEL Assay
Specimens were obtained from storage in a freezer at 80°C and
allowed to warm to approximately 22°C in the cryostat. Four
adjacent sections, midway between the base and the apex, span-
ning the BZ were prepared to measure apoptosis. TUNEL assay
(TdT-mediated dUTP nick-end labeling) was performed with a
TdT-FragEL DNA Fragmentation Detection Kit (Oncogene Re-
search Products, Boston, Mass). The apoptotic index was taken as
a percentage of total apoptotic nuclei per high-powered field
examined. Five measurements were obtained from the free wall of
each section, by each of two investigators, blinded to the treatment
group. The results are reported as the apoptotic indices for each
heart  SEM.
Immunoblotting
Specimens obtained for Western blotting were snap-frozen in
liquid nitrogen after removal from the animal, without O.C.T.
fixative. Specimens were pulverized, homogenized in 10 volume
of sodium dodecylsulfate (SDS) lysis buffer (100 mmol/L Tris, pH
8.0, 10% SDS, 10 mmol/L ethylenediamine tetraacetic acid, 50
mmol/L dithiothreitol (DTT), and sheared with a 25-gauge needle.
Samples were normalized for total protein content, and 50 g of
each sample were electrophoresed on a 12.5% SDS-polyacryl-
amide gel after the addition of 6X sample loading buffer and 3
minutes of denaturation at 100°C. Proteins were then transferred to
Immobilon-P (Millipore, Bedford, Mass) with a wet transfer ap-
paratus. The membrane was subsequently blocked with 5% nonfat
dry milk in Tris-buffered saline solution containing 0.05% Tween
20. Immunoblotting was performed with a polyclonal antibody
against human ARC at a 1:100 dilution.22 Detection was per-
formed with the ECL kit (Amersham, Piscataway, NJ).
Statistical Analysis
All data are expressed as mean value  SEM. Statistical analyses
were performed with INSTAT (GraphPad Software, Sorrento Val-
ley, Calif). Comparisons between 2 groups were analyzed by
unpaired Student’s t test. Multiple comparisons against the control
were first analyzed by 1-way analysis of variance followed by the
Tukey-Kramer modified unpaired Student’s t test to determine
significance between groups.
Results
Demonstration of Global Delivery and Transgene
Expression
An adenoviral construct containing the -Gal reporter gene
was used with this technique of viral delivery demonstrating
transfection of approximately 30% to 35% of myocardium
preferentially in the BZ and LV free wall (Figure 3). Im-
munoblotting demonstrated increased expression of ARC at
the BZ in the Adeno-ARC treated group compared with the
controls at 6 weeks as seen in Figure 2.
Improvement of LV Function After Adeno-ARC
Treatment
Baseline ejection fraction for a group of native rabbits (n 
5) before surgery was 42%  1.2%. Two weeks after
ischemia, there was no difference in ejection fraction be-
tween the Adeno-ARC (A) and the control (C) groups (A
35%  3.1% and C  32%  1.5%; P  .41. However,
ARC rabbits demonstrated greater preservation of function
than did at 4 weeks (A  38%  1.9% and N  29% 
Figure 3. Gene transfection. Demonstration of transfection effi-
ciency by global delivery with great vessel occlusion. Staining
for -Gal demonstrates that transgene is preferably taken up in
BZ region after 30 minutes of ischemia/reperfusion with trans-
fection of approximately 30% to 35% of myocardium.
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2.0%; P  .001) and at 6 weeks (A  36%  3.1%, C
27%  1.8%; P  .001). In addition, whereas the control
rabbits had a continued decline in function between weeks
2 and 6 (P  .01), the ARC group maintained function
between weeks 2 and 6 (P .80). Although the ARC group
was superior to the control group, it was still less than the
native group at each time point (P  .01) (Figure 4).
Preservation of fractional shortening in the ARC group at 6
weeks was significantly greater than that in the control
group (A  70.81%  8.79% and C  49.76%  2.22%;
P  .048) (Figure 5).
Preservation of Ventricular Geometry
Compared with native rabbits (uninfarcted and untreated),
the Adeno-ARC group demonstrated superior preservation
of ventricular geometry and wall thickness than the controls.
Rabbits treated with gene transfer of ARC had a mean
chamber diameter of 13.59  0.47 mm (native [N] 
13.44  0.56 mm, P  .84) and free wall thickness of
3.48  0.18 mm (N  3.61  0.10 mm, P  .54). Control
rabbits had a significant increase in mean LV mid-chamber
diameter (C  16.87  0.88 mm; P  .01 compared with
both native and Adeno-ARC) and loss of wall thickness
(C  2.57  0.15 mm; P  .01 compared with both native
and Adeno-ARC). The results are summarized in Figures 6
and 7. A representative sample from each of the 3 groups is
seen in Figure 8.
Demonstration of Apoptosis
The number of apoptotic cells was expressed as a percent-
age of total nuclei per high-powered field examined. A
significant reduction in apoptosis in the ARC-treated group
(0.77%  0.16%; P  .0001) compared with the controls
(2.77%  0.35%) was observed (Figure 9). Representative
sections are depicted in Figure 10.
Conclusions
This study demonstrates that adenoviral gene therapy with
ARC can block apoptosis after myocardial ischemia to
preserve ventricular function and geometry over a 6-week
course in a rabbit model. This is the first in vivo study to use
Adeno-ARC.
Our method of viral gene delivery with aortic and pul-
monary artery occlusion resulted in transfection of 30% to
35% of the myocardium, preferentially in the BZ and LV
free wall. The advantage to occlusion of the PA before
aortic occlusion is the opportunity for the left atrium and
ventricle to empty lowering LV end-diastolic volume reduc-
ing LV end-diastolic pressure. As a result, intracavitary
injection of the viral vector with both aortic and PA occlu-
sion allows greater diffusion into the coronary arteries and
the myocardial capillary bed because the reduced LV end-
diastolic pressure creates a more favorable gradient for the
virus to transfect the myocardium. In addition, there is less
hemodynamic dysfunction by avoiding a more distended
left ventricle beating against an occluded aorta. The prefer-
ential localization into the BZ may be due to alterations in
endothelial cell permeability in this region after ischemia. In
addition, transgene expression of ARC was elevated in the
Adeno-ARC group 6 weeks after delivery, demonstrating
feasibility of delivery.
We expect that the administration of ARC after the
immediate ischemia/reperfusion insult would not confer a
protective benefit for at least 1 to 2 days because that would
be the minimal amount of time required for viral gene
expression to first be detected. At 2 weeks both groups of
Figure 4. Echocardiography. Global myocardial function measured by LV ejection fraction from transthoracic
echocardiography. At 2 weeks, there is no significant difference among the 3 groups. However, ARC-treated
animals maintained higher EF at weeks 4 and 6 compared with the Adeno-null controls. For ARC-treated animals
compared with controls at the same time point: *P NS; **P < .001. Comparison of control week 2 to control week
6 (#P < .01), and comparison of ARC week 2 to ARC week 6 (##P  NS).
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animals experience a decline in function caused by the
infarction as seen by echocardiography. However, by 4
weeks the benefit in the ARC group is apparent and con-
tinues at 6 weeks. Importantly, despite the initial decline in
EF after infarction seen at 2 weeks, there was no continued
decline in the ARC group as opposed to the continuous
deterioration in function seen in the controls. This suggests
that ARC can prevent a decline in function.
By 6 weeks, regional function with sonomicrometry
demonstrates greater preservation of contractility across the
BZ in ARC animals. The ratio of preservation of fractional
shortening across the BZ compared with the viable myocar-
dium serves as a control against the contractile state of the
heart. LV function after infarction is first maintained by
hypertrophy in the BZ region, and then the remaining myo-
cardium is recruited as needed to hypertrophy in an effort to
maintain stroke volume. The transition to decompensated
hypertrophy is characterized by a decline in contractility
across the BZ followed by further hypertrophy in the re-
maining myocardium until the remaining myocardium can
no longer compensate and heart failure ensues. This analy-
sis, as a result, allowed us to determine the specific con-
tractility of the BZ with respect to the remaining myocar-
dium. Most important, the correlation of the preservation of
fractional shortening with echocardiography served as a
validation for both techniques of analysis in this rabbit
model.
In addition to a significant number of myocytes under-
going apoptosis in the ischemic segment during the initial
period of ischemia/reperfusion injury, it appears that apo-
ptosis is present at the BZ beyond the initial injury. Initial
myocyte loss may be coupled with additional cell loss over
time due to apoptosis. Although the TUNEL assay is not
Figure 5. Sonomicrometry. There is superior preservation of fractional shortening (FS) across BZ in the ARC group
at 6 weeks compared with the Adeno-null controls. Results are reported as a percentage of baseline FS of BZ
compared with remote viable myocardium. (*P < .05 for ARC compared with controls.)
Figure 6. Assessment of LV chamber size. LV dilation was mea-
sured by ventricular diameter at the BZ. (*P < .01 when compared
with Adeno-null control group. #P  NS and ##P < .01 when
compared with native group.) Figure 7. Assessment of LV free wall thinning. LV free wall
thinning at BZ was measured by LV free wall thickness. (*P < .01
when compared with Adeno-null control group. #P  NS and
##P < .01 when compared with native group.)
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specific for cardiomyocytes, recent reports have determined
that nearly all apoptotic bodies are cardiomyocytes.18,19
Olivetti noted that the mechanism of ventricular wall thin-
ning of the remaining myocardium was the result of a 36%
reduction in the mural number of myocytes over time.1 This
cell loss within the myocardium may further destabilize the
ventricular scaffolding resulting in cell-cell slippage of the
remaining myocytes.3 Thus, the lateral slippage of myocytes
may condition the onset, development, and progression of
heart failure that evolves after an acute myocardial infarc-
tion.20
This study suggests that apoptosis exacerbates myocar-
dial cell death after infarction resulting in progressive ven-
tricular dilation. The trigger for apoptosis over the chronic
period may be due to the abnormal passive stretching pro-
duced by bulging of the necrotic infarct region during
ventricular contraction across the BZ.21 It appears that pro-
gressive stretch leads to an increase in cytosolic calcium
levels destabilizing the mitochondrial membrane and trig-
gering the release of cytochrome-c and apoptosis.22 As the
mechanical disadvantage of higher wall tension is aug-
mented with infarct maturation, ventricular stiffening, and
progressive chamber dilation, the continued stretch across
the BZ may initiate and sustain further apoptosis through
multiple mechanisms. Thus, the benefit over the course of 6
weeks in the ARC-treated group would likely be due to an
anti-apoptotic effect that occurs after the initial ischemia/
reperfusion injury.
Multiple theories exist to explain global LV dysfunction
with respect to dysfunction of the BZ, a region of normally
perfused but poorly functioning myocardium.23 Increased
wall stress in the BZ after myocardial infarction has been
demonstrated as a result of mechanical tethering of the BZ
region to adjacent noncontracting myocardium.24,25 This has
also been shown to lead to increased apoptosis in the BZ. In
addition, pathologic alterations in the BZ may occur be-
cause the oxygenation potential of the surviving myocar-
dium is significantly reduced in this region, making the cells
more susceptible to additional ischemic episodes.26 Thus,
BZ dysfunction is likely multifactorial after ischemia.
There was a significant reduction in the degree of apo-
ptosis in the ARC-treated group (0.77%  0.15%) com-
pared with the controls (2.77% 0.35%). Although there is
wide variability in terms of the extent of apoptosis reported
after myocardial ischemia, these data are consistent with
other studies. Olivetti and associates26 noted 12% of myo-
cytes in the BZ and 1% of myocytes in the remote myocar-
dium showed apoptosis in patients who died within 10 days
after myocardial infarction. Sharov and coworkers27 noted
4% in the BZ and less than 0.5% in the remote myocardium
in a dog model of infarction and subsequent heart failure.
Overexpression of ARC appears to have conferred signifi-
Figure 9. Apoptotic index. A significant reduction in the percent-
age of apoptotic cells in the ARC group compared with the
controls after 6 weeks is demonstrated. (*P < .0001 when com-
pared with control rabbits.)
Figure 8. Representative sections at BZ. Representative mid chamber sections are depicted above. Left, Native
(uninfarcted and untreated); middle, Adeno-null control; right, Adeno-ARC. ARC-treated group preserved midcham-
ber transverse diameter and LV free wall thickness to a greater extent when compared with natives than the
control group.
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cant protection from apoptosis during the entire 6 weeks
examined whereas gene expression was maintained. It
would be important to determine whether this protective
effect of ARC would still be present over a longer period
once the gene was no longer expressed. It may be that
further long-term protection requires continued ARC ex-
pression; on the other hand, it may be that ARC is only
required during a critical period soon after the infarction to
“rescue” the heart by blocking apoptosis.
We postulate that apoptosis persists within the BZ region
after infarction, which contributes to myocardial stretch and
eventual ventricular dilation and dysfunction. The data sug-
gest that blocking apoptosis in this region can prevent
pathologic ventricular remodeling. Administration of Ad-
eno-ARC leads to a reduction in apoptosis, preservation of
ventricular geometry, and prevention of postischemic heart
failure. As the limitations of gene therapy are overcome, its
ultimate clinical application as an adjunct to the conven-
tional pharmacologic and interventional management of
myocardial infarction may be approaching. This study rep-
resents a small, preliminary yet important step to this goal.
There are a number of issues that will have to eventually be
worked out, such as the ideal vector for delivery, the ideal
method of delivery (direct intramyocardial injection vs in-
tracoronary delivery with coronary angiography vs intracav-
itary delivery with temporary outflow occlusion), and the
optimal timing after myocardial infarction during which to
attempt delivery, among others. Nevertheless, the potential
application of this strategy and clinical benefit is readily
apparent.
We are grateful to Timothy Pirolli and Jeffrey Burdick for
technical support.
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Discussion
Dr G. Alexander Patterson (St Louis, Mo). The distribution of
the transfection was not entirely clear to me. You showed a very
nice slide of the distribution of -Gal, and it struck me that most
of the distribution was on the epicardium, not within the cardiac
muscle itself. It seemed to me a very superficial distribution. Do
you have any immunohistochemistry or some other assay that
would allow us to know the distribution of the Adeno-ARC? Is it
the same as that of -Gal?
Dr Chatterjee. The -Gal distribution is both within the epi-
cardium and also within most of the myocardium. In terms of
Adeno-ARC expression, what we relied on was immunoblotting at
6 weeks after injection. This showed that there was a significant
increase, about a 20-fold increase in intensity, within the BZ
region of the heart.
Interestingly, when we compared Adeno-ARC expression in
the viable normal myocardium outside the infarct region, there was
only a very small increase in expression in the ARC-treated group
compared with the null controls. So, according to our immuno-
blotting at 6 weeks, there appears to be preferential localization of
Adeno-ARC within the BZ region as opposed to other regions of
the heart.
Dr Christopher A. Caldarone (Iowa City, Iowa). I was inter-
ested in the mechanism of ARC in the myocyte. You pointed out
that it worked at the level of caspase 8 and preventing release of
cytochrome C, presumably resulting in less caspase activity down-
stream. Did you make any attempt to measure caspase activity in
these specimens? The other question was in reference to the
apoptotic index.
Dr Chatterjee. In terms of measuring caspase activity, that is
a very good point. The next step in this study is looking at caspase
3 activity, as well as caspase 8 levels within our treated samples to
determine how much of a reduction occurs. In vitro evidence
demonstrates that in cell lines, injecting Adeno-ARC can block
both caspase 8 in the extrinsic pathway of apoptosis, as well as the
release of cytochrome C from the mitochondria in the intrinsic
pathway. Much of this is believed to be mediated by preventing
reactive oxygen species activity that results from ischemic injury.
In terms of your second question, the apoptotic index was the
percent of cells per high-powered field that were apoptotic. In the
control group it was about 2.7%, and in the ARC-treated group it
was 0.7%, a 4-fold reduction.
Dr Caldarone. The reason that first question might be pertinent
is because a recent study in human dilated ischemic cardiomyop-
athy demonstrated apoptosis occurring through caspase-indepen-
dent mechanisms. Therefore, I believe measuring the caspase
activity would be important.
Dr Chatterjee. Certainly. What is interesting with ARC is that
ARC has been shown to work not only in the caspase-dependent,
the death receptor-mediated pathway mediated by tumor necrosis
factor receptor 1, but also through the caspase-independent path-
way, as you mentioned, through cytochrome c. The benefit of
ARC, in theory, is that it acts on both arms of the apoptotic
cascade, and certainly in vitro evidence demonstrates a significant
reduction in downstream caspase 3 activity, the final common
pathway of apoptosis.
Dr Ralph J. Damiano, Jr (St Louis, Mo). One possibility, and
you mentioned it in your introduction, is that ARC may also have
a beneficial effect on preventing necrosis. Did you look at infarct
size in these animals, particularly in the area at risk? Was there any
effect on cell necrosis as contrasted to its primary effect on
apoptosis?
Dr Chatterjee. That is an excellent point. We have actually
looked at other anti-apoptotic agents in a similar model, and in
those groups we have seen no real change in the size of the infarct.
Our theory is that the size of the infarct is largely determined right
away in the first 24 hours; however, it really takes about 48 to 72
hours before transgene expression begins and ARC can exert a
protective effect. The acute infarct size is probably determined
before ARC is even expressed. What we do see is a small increase
in fibrosis within the BZ of the null group, suggesting that there
may be, in addition to blocking apoptosis, some antinecrosis
benefit within the BZ region of the ARC-treated group.
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